JP2025513850A5 - - Google Patents

Info

Publication number
JP2025513850A5
JP2025513850A5 JP2024560404A JP2024560404A JP2025513850A5 JP 2025513850 A5 JP2025513850 A5 JP 2025513850A5 JP 2024560404 A JP2024560404 A JP 2024560404A JP 2024560404 A JP2024560404 A JP 2024560404A JP 2025513850 A5 JP2025513850 A5 JP 2025513850A5
Authority
JP
Japan
Prior art keywords
capsid
irak
pharmaceutical composition
aav
viral vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024560404A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025513850A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/065687 external-priority patent/WO2023201272A1/en
Publication of JP2025513850A publication Critical patent/JP2025513850A/ja
Publication of JP2025513850A5 publication Critical patent/JP2025513850A5/ja
Pending legal-status Critical Current

Links

JP2024560404A 2022-04-12 2023-04-12 遺伝子治療のためのirak4モジュレーターの使用 Pending JP2025513850A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263330239P 2022-04-12 2022-04-12
US63/330,239 2022-04-12
PCT/US2023/065687 WO2023201272A1 (en) 2022-04-12 2023-04-12 Use of irak4 modulators for gene therapy

Publications (2)

Publication Number Publication Date
JP2025513850A JP2025513850A (ja) 2025-04-30
JP2025513850A5 true JP2025513850A5 (https=) 2026-04-20

Family

ID=86329443

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024560404A Pending JP2025513850A (ja) 2022-04-12 2023-04-12 遺伝子治療のためのirak4モジュレーターの使用

Country Status (11)

Country Link
US (1) US20230405151A1 (https=)
EP (1) EP4508225A1 (https=)
JP (1) JP2025513850A (https=)
KR (1) KR20250004740A (https=)
CN (1) CN119630802A (https=)
AU (1) AU2023252915A1 (https=)
CA (1) CA3248481A1 (https=)
IL (1) IL316231A (https=)
MX (1) MX2024012616A (https=)
TW (1) TW202400250A (https=)
WO (1) WO2023201272A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12022500002A1 (en) 2019-06-28 2023-04-03 Kymera Therapeutics Inc Irak degraders and uses thereof
WO2021011868A1 (en) 2019-07-17 2021-01-21 Kymera Therapeutics, Inc. Irak degraders and uses thereof
WO2021119159A1 (en) 2019-12-10 2021-06-17 Kymera Therapeutics, Inc. Irak degraders and uses thereof
KR20220145325A (ko) 2019-12-17 2022-10-28 카이메라 쎄라퓨틱스 인코포레이티드 Irak 분해제 및 이의 용도

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0931158A1 (en) 1996-09-06 1999-07-28 The Trustees Of The University Of Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase
US6989264B2 (en) 1997-09-05 2006-01-24 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
CA2379166C (en) 1999-08-09 2013-03-26 Targeted Genetics Corporation Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms instrastrand base pairs
US6818419B2 (en) 2000-01-13 2004-11-16 Tularik Inc. IRAK-4: compositions and methods of use
ATE318923T1 (de) 2000-06-01 2006-03-15 Univ North Carolina Doppelsträngige parvovirus-vektoren
US7510872B2 (en) 2003-02-26 2009-03-31 Nationwide Children's Hospital Recombinant adeno-associated virus production
US7261544B2 (en) 2003-05-21 2007-08-28 Genzyme Corporation Methods for producing preparations of recombinant AAV virions substantially free of empty capsids
US20100279316A1 (en) 2007-01-19 2010-11-04 Leonid Gorelik Antibodies to Phosphorylated IRAK4
KR20180000341A (ko) 2009-06-16 2018-01-02 젠자임 코포레이션 재조합 aav 벡터에 대한 개선된 정제 방법
US20110070241A1 (en) * 2009-06-30 2011-03-24 Duke University Methods for modulating immune responses to aav gene therapy vectors
EP2561073B1 (en) 2010-04-23 2016-08-24 University of Massachusetts Cns targeting aav vectors and methods of use thereof
KR20160145803A (ko) 2014-04-22 2016-12-20 님버스 아이리스 인코포레이티드 Irak 억제제 및 이의 용도
EP3200788B1 (en) 2014-09-30 2019-09-18 Merck Sharp & Dohme Corp. Inhibitors of irak4 activity
WO2016144847A1 (en) 2015-03-12 2016-09-15 Merck Sharp & Dohme Corp. Pyrrolopyridazine inhibitors of irak4 activity
WO2017004133A1 (en) 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
CN108024971A (zh) 2015-07-15 2018-05-11 奥列基因发现技术有限公司 作为irak-4抑制剂的取代的氮杂化合物
KR102110573B1 (ko) 2015-08-13 2020-05-13 베이징 한미 파마슈티컬 컴퍼니 리미티드 Irak4억제제 및 이의 용도
ES2946001T3 (es) 2016-10-26 2023-07-11 Rigel Pharmaceuticals Inc Compuestos de pirazol amida como inhibidores de IRAK
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
US11542251B2 (en) 2018-02-14 2023-01-03 Dana-Farber Cancer Institute, Inc. IRAK degraders and uses thereof
IL277408B2 (en) 2018-04-05 2024-08-01 Merck Patent Gmbh Heteroaryl compounds as IRAK type II inhibitors and their use
US12060366B2 (en) 2018-06-29 2024-08-13 Dana-Farber Cancer Institute, Inc. Bispecific degraders
CA3119773A1 (en) 2018-11-30 2020-06-04 Kymera Therapeutics, Inc. Irak degraders and uses thereof
WO2020264490A1 (en) 2019-06-28 2020-12-30 Kymera Therapeutics, Inc. Irak degraders and uses thereof
WO2021011868A1 (en) 2019-07-17 2021-01-21 Kymera Therapeutics, Inc. Irak degraders and uses thereof
EP4076524A4 (en) 2019-12-17 2023-11-29 Kymera Therapeutics, Inc. IRAQ DEGRADERS AND USES THEREOF
WO2021168197A1 (en) 2020-02-19 2021-08-26 Nurix Therapeutics, Inc. Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof
EP4149622A4 (en) * 2020-05-12 2024-12-18 Myogene Bio LLC IMMUNOSUPPRESSIVE AGENTS AND METHODS OF RE-DOSING VIRAL ADMINISTRATION FOR GENE THERAPY
US20230250110A1 (en) 2020-06-03 2023-08-10 Kymera Therapeutics, Inc. Deuterated irak degraders and uses thereof
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型

Similar Documents

Publication Publication Date Title
JP2025513850A5 (https=)
US20210285012A1 (en) Method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
CN108602859B (zh) 增强细小病毒载体递送的修饰衣壳蛋白
CN102174574B (zh) 腺伴随病毒(aav)进化支、序列、含有这些序列的载体及它们的应用
JP2024149508A (ja) 新規アデノ随伴ウイルス(aav)バリアント及び遺伝子治療のためのその使用
TW201629225A (zh) 第九因子基因療法
JP2025513851A5 (https=)
JP2022545121A (ja) Aav5の単離修飾vp1カプシドタンパク質
CN111876432B (zh) 一组肝靶向新型腺相关病毒的获得及其应用
US11077208B2 (en) Wilson's disease gene therapy
JP2023513932A (ja) X連鎖障害の治療におけるmiRNAのAAV媒介標的化
TW202405430A (zh) 對於基因療法藥劑的先天免疫原性之樹突細胞試驗
RU2024133631A (ru) Применение модуляторов irak4 для генной терапии
Еpifanova et al. Viral Vectors for Delivering Gene Material into Cells and Their Application in Neurobiology
EA050477B1 (ru) Доставка альфа-саркогликана с помощью вектора на основе аденоассоциированного вируса и лечение мышечной дистрофии
HU230093B1 (hu) Eljárás adeno-asszociált vírus(AAV)szekvenciák detektálására és/vagy azonosítására, és az azzal azonosított új szekvenciák izolálására
HK1068925B (en) A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
HK1260937B (en) Modified capsid proteins for enhanced delivery of parvovirus vectors